Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
source : Www.biospace.com save search
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
Published: 2023-12-01 (Crawled : 23:00) - biospace.com/
VCYT | $26.54 3.67% 0.15% 580K
|
Health Technology
|
| O: -1.99%
H: 0.0%
C: 0.0%
genomic cancer show
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Published: 2023-12-01 (Crawled : 22:00) - biospace.com/
PFE | $28.91 -5.12% 0.0% 100M
|
Health Technology
|
| O: -4.15%
H: 0.0%
C: 0.0%
obesity topline results
Neurocrine Biosciences to Host Analyst Day on December 5, 2023
Published: 2023-12-01 (Crawled : 20:00) - biospace.com/
NBIX S | $117.12 0.46% 0.75% 1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
day
Biopharma Layoff Tracker 2023: Pfizer, Orna, Kite and More Cut Staff
Published: 2023-12-01 (Crawled : 17:00) - biospace.com/
JNJ | $158.38 2.41% 0.0% 10M
|
Health Technology
|
| O: 1.18%
H: 0.0%
C: 0.0%
VXRT | $0.7299 2.08% -0.69% 460K
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
TXMD | $2.74 6.2% -4.75% 18K
|
Health Technology
|
| O: 5.43%
H: 0.0%
C: 0.0%
PTCT | $23.99 4.21% -0.21% 1.1M
|
Health Technology
|
| O: -2.93%
H: 0.0%
C: 0.0%
NKTR | $0.525 7.14% 0.0% 1.1M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
MOR | $7.01 2.49% -0.57% 2.4M
|
Health Technology
|
| O: -7.16%
H: 0.0%
C: 0.0%
AMRN | $0.75 -4.09% 0.68% 1.7M
|
Health Technology
|
| O: -2.81%
H: 0.0%
C: 0.0%
GOOGL S | $131.86 -0.51% 0.08% 31M
|
Technology Services
|
| O: -2.4%
H: 0.0%
C: 0.0%
GOOG | $133.32 -0.45% 0.14% 24M
|
Technology Services
|
| O: -0.44%
H: 0.0%
C: 0.0%
biopharma
Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink
Published: 2023-12-01 (Crawled : 16:00) - biospace.com/
TMO | $496.13 0.08% 0.0% 1.2M
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
olink
Kazia Therapeutics Announces $2 Million Registered Direct Offering
Published: 2023-12-01 (Crawled : 16:00) - biospace.com/
KZIA 2 d | $0.451 -19.56% 0.22% 200K
|
Health Technology
|
| O: -16.0%
H: 0.0%
C: 0.0%
direct offering therapeutics
NeuroBo to Participate in Investor Conferences in December
Published: 2023-12-01 (Crawled : 16:00) - biospace.com/
NRBO | $0.4499 0.42% 0.0% 31K
|
Health Technology
|
| O: -1.34%
H: 0.0%
C: 0.0%
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
Published: 2023-12-01 (Crawled : 16:00) - biospace.com/
FBIO | $2.17 9.6% 0.46% 450K
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
ATXI | $0.192 -9.43% 1.98% 4.5M
|
Health Technology
|
| O: -8.49%
H: 0.0%
C: 0.0%
meeting therapeutics
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
Published: 2023-12-01 (Crawled : 16:00) - biospace.com/
STOK | $3.95 4.22% 0.0% 140K
|
Health Technology
|
| O: 0.39%
H: 0.0%
C: 0.0%
children meeting therapeutics
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
Published: 2023-12-01 (Crawled : 15:30) - biospace.com/
CING | $6.27 1.13% -5.1% 79K
|
|
| O: 1735.48%
H: 0.0%
C: 0.0%
fda
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
JAZZ | $119.11 0.74% 0.0% 640K
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
pharmaceuticals meeting
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
WGS | $1.8 2.86% 2.78% 280K
|
Professional, Scientific, and T...
|
| O: -0.57%
H: 0.0%
C: 0.0%
meeting
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
INTS | $3.15 28.55% -5.71% 22K
|
|
| O: 8.61%
H: 0.0%
C: 0.0%
breast symposium presentation cancer therapeutics
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
OVID | $3.195 7.4% 0.16% 110K
|
Health Technology
|
| O: 3.53%
H: 0.0%
C: 0.0%
meeting therapeutics
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
LGND | $58.75 0.76% 2.3% 74K
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
partnership pharmaceuticals therapeutics
Allogene Therapeutics Announces Participation in December Investor Conference
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
ALLO | $2.52 7.23% 0.0% 2.4M
|
Health Technology
|
| O: 3.95%
H: 0.0%
C: 0.0%
conference therapeutics
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
TOT | $48.3 0%
|
Energy Minerals
| Email alert
Add to watchlist
nrtx-1001 cell ongoing trial therapeutics therapy
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
NPCE S | $8.9 -1.0% 0.0% 30K
|
Manufacturing
|
| O: 0.51%
H: 0.0%
C: 0.0%
system meeting
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
GANX | $2.2 2.8% 10.32% 53K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
preclinical therapeutics
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
NAVB | $0.0699 39.52% -43.49% 680K
|
Health Technology
| Email alert
Add to watchlist
royalty agreement
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.